济南前列腺不舒服(济南前列线肥大如何治疗) (今日更新中)

BEIJING, Sept. 28 (Xinhua) -- Chinese banks have extended more loans to small firms to ease their financial predicaments as the government tightens monetary supply, a banking regulator said Wednesday.Outstanding loans to small firms grew 26.6 percent year-on-year to hit 9.85 trillion yuan (1.55 trillion U.S. dollars) at the end of July, said Xiao Yuanqi, an official in charge of financial services for small enterprises at the China Banking Regulatory Commission.The growth was 10 percentage points higher than that of the banks' total outstanding loans, Xiao told Xinhua.More than 100 commercial banks have set up special operations to ease small firms' difficulties getting access to bank credit, he noted.The figures came at a time when China is trying to balance the missions of countering inflation and sustaining the growth of small enterprises.The People's Bank of China, or the central bank, has raised the benchmark interest rate three times this year and increased the reserve requirement ratio six times.The measures bit into small, cash-strapped companies, which are already disadvantaged in seeking bank support due to insufficient collateral.Only 15 percent of China's small enterprises could get loans from banks and half of them had to resort to private lenders, according to a report by the National School of Development with Peking University in July.With tighter liquidity and stricter regulatory requirements on capital-adequacy ratios and loan-deposit ratios, banks are more reluctant to lend to small firms, said Ai Min, a retail banking general manager with China Minsheng Banking Corp., Ltd.Besides, the expanding size of lending to small firms may lead to higher risks, said Ai.He suggested banks improve the risk evaluation and collateral system for loans to small firms.

LOS ANGELES, June 5 (Xinhua) -- U.S. researchers have developed two new drugs that can prolong the lives of patients with advanced melanoma, it was announced on Sunday.Research on both drugs was presented at the on-going annual meeting of the American Society of Clinical Oncology in Chicago, according to HealthDay News.This is the first big news in years for treatment of melanoma, one of the deadliest forms of skin cancer and one that is notoriously difficult to treat, let alone cure, the report said.The first treatment, vemurafenib, inhibits a gene mutation harbored in half of all melanoma patients, but is not yet approved by the U.S. Food and Drug Administration.The other drug, Yervoy (ipilumumab), is an immune system therapy that won approval in March."The March FDA approval of ipilumumab (Yervoy) was the first new drug approval for melanoma in 13 years," said Tim Turnham, executive director of the Melanoma Research Foundation.The two drugs were developed by researchers at Memorial Sloan- Kettering Cancer Center in New York City, the report said."This is really a huge step toward personalized care in melanoma," Dr. Paul Chapman, lead author of the first study and the attending physician in the melanoma/sarcoma service at Memorial Sloan-Kettering, said in a statement. "This (vemurafenib) is the first successful melanoma treatment tailored to patients who carry a specific gene mutation in their tumor, and could eventually become one of only two drugs available that improves overall survival in advanced cancers.""Having two trials that show a benefit in survival in patients with melanoma, both of these in first-line settings -- we weren't here just a few years ago," said Dr. Stephen Hodi, director of the Melanoma Center at Dana Farber Cancer Institute in Boston. "These are huge, paradigm-shifting results for the field."In the vemurafenib trial, sponsored by the drug's makers, researchers randomly assigned 675 patients with advanced, inoperable melanoma to receive either the chemotherapy drug dacarbazine or vemurafenib. Vemurafenib targets the V600E mutation in the BRAF gene.At the three-month mark, patients taking vemurafenib were 63 percent less likely to die and 74 percent less likely to die or see their cancer return, compared to patients taking dacarbazine alone.Few patients had side effects in the vemurafenib group, although some did develop squamous cell carcinoma, a less dangerous form of skin cancer.This is the first drug that has been proven superior to chemotherapy in this group of hard-to-treat patients, the researchers said."There was such a substantial benefit that we recommended that patients cross over," Chapman said at a Sunday news briefing. "It' s unprecedented to report a trial this early. The median follow-up time was three months." Yet the differences between the two groups became evident almost immediately.Dr. Lynn Schuchter, co-moderator of the briefing and division chief of hematology-oncology at Abramson Cancer Center of the University of Pennsylvania in Philadelphia, said symptoms subsided in some patients almost immediately, enabling them to cut back on pain medication in just 72 hours."The median time to progression with dacarbazine was 1.6 months versus three months with vemurafenib, which is a huge difference," said Chapman.In the second study, about 500 patients were randomly picked to receive Yervoy plus dacarbazine or dacarbazine alone.Those taking both drugs lived a median of 11.2 months compared to 9.1 months for those taking dacarbazine alone. Time to recurrence of disease was about the same for both groups: 2.8 months and 2.6 months, respectively.Almost half of those taking the combination therapy were alive after one year, compared to 36.3 percent in the other group. After two years, the rates were 28.5 percent and 17.9 percent, respectively.By three years out, 20.8 percent of those in the combination group were alive compared with 12.2 percent of those taking chemotherapy alone.This is the first study to combine chemotherapy and immunotherapy both safely and effectively.A study to test vemurafenib in combination with Yervoy has already begun, according to HealthDay News.

BEIJING, June 29 (Xinhuanet) -- Twitter Inc. co-founders Biz Stone and Evan Williams said they are moving on from the microblogging service, media reports said Wednesday.“The Twitter crew and its leadership team have grown incredibly productive,” Stone said on the blog. “I’ve decided that the most effective use of my time is to get out of the way until I’m called upon to be of some specific use.”The two will continue to advise Twitter on strategic matters, but devote the lions' share of their time to The Obvious Corporation, Stone said.Obvious was first created by Williams to buy back a company from investors that he and Stone failed to sell about six years ago, Stone said. The two began working together after leaving Google in 2005.The company will also be run by Jason Goldman, a former Twitter executive, Stone said.

SEOUL, Sept. 26 (Xinhua) -- Samsung Electronics, the world's second-largest manufacturer of mobile phones, launched its first smartphones based on fourth-generation (4G) communication technology in a bid to meet growing demand for high-speed wireless services. Galaxy S2 LTE and Galaxy S2 HD LTE compatible with long- term evolution (LTE) technology were rolled out at a media event held in central Seoul on Monday. The two new smartphones support LTE with data transmission five times faster than the existing third-generation (3G) mobile phones, featuring functions offered by Galaxy S2 smartphones, the company said.The Galaxy S2 LTE is equipped with an Android 2.3, or the latest version of the Android platform, a 4.5-inch wide Super AMOLED display and a 1.5 gigahertz dual core processor, while the Galaxy S2 HD LTE is featuring a 4.65-inch high-definition (HD) AMOLED display with 110 percent natural color reproduction and 180- degree viewing angle. "The 4G LTE technology became the base for enjoying high-speed and high-resolution wireless services. The new products will meet rising demand for such services in an environment where global wireless operators are transitioning to 4G networks," Shin Jong-kyun, president and head of Samsung's mobile communications business, told reporters.Shin forecast sales of the new LTE smartphones would approach the ones of the existing Galaxy S series, adding that it may take time to reach the goal as the LTE networks have yet to be covered nationwide.Global sales of the Galaxy S2 smartphones reached more than 10 million units since its debut in April, according Samsung. The nation's top wireless carrier SK Telecom plans to offer LTE service nationwide by 2013, with the country's No. 3 mobile operator LG Uplus aiming to cover the service across the country next year.

来源：资阳报